Form 4: VolitionRx Director Innes Boosts Stake with New Purchase

VolitionRx Director Guy Archibald Innes acquired 96,153 shares of common stock and accompanying warrants in a public offering, increasing his direct beneficial ownership.

Summary

• Director Guy Archibald Innes purchased 96,153 shares of VolitionRx Ltd. common stock.
• The purchase price for the common stock was $0.51 per share.
• Concurrently, Innes acquired 96,153 common stock warrants, each allocated a price of $0.01.
• These warrants have an exercise price of $0.60 per share and expire on October 14, 2030.
• The transaction was part of an underwritten public offering by the Issuer, which closed on October 14, 2025.
• Following this transaction, Innes directly beneficially owns 1,062,967 shares of common stock and 96,153 warrants.
• Indirect beneficial ownership includes 1,400,000 shares via The Innes Family Bare Trust 2023, 356,000 shares via The Dill Faulkes Educational Trust Limited, and 618,014 shares through his children.

Sentiment

Score: 8

Explanation: A director's purchase of a significant number of shares and warrants, especially as part of a public offering, typically indicates strong confidence in the company's valuation and future prospects. This is generally viewed positively by the market.

Positives

• A director increasing their stake in the company signals confidence in its future prospects.
• The purchase was made in connection with a public offering, indicating participation in a broader capital raise.

Negatives

• No explicit negatives are reported in this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an insider transaction, specifically a director's purchase of company stock and warrants. While not directly related to broader industry trends, such transactions can reflect internal perceptions of company value within its sector.

Comparison to Industry Standards

• Not applicable. This Form 4 reports an individual insider transaction and does not provide data for comparison against industry-wide financial or operational benchmarks.

Related Party Transactions

• The reporting person serves as a Trustee for The Innes Family Bare Trust 2023, which beneficially owns 1,400,000 shares.
• The reporting person serves as a director and trustee of The Dill Faulkes Educational Trust Limited, which beneficially owns 356,000 shares, though he disclaims beneficial ownership except for his pecuniary interest.
• The reporting person also reports indirect beneficial ownership of shares through his sons and daughters.

Stakeholder Impact

• Shareholders: The director's increased stake may instill greater confidence among existing and potential shareholders, signaling alignment of interests and belief in the company's future.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The director's decision to significantly increase his direct stake in VolitionRx, particularly through participation in a public offering, is a strong positive signal. This insider buying suggests management confidence in the company's current valuation and future growth trajectory, making it a favorable indicator for potential investors.

Keywords

VolitionRx, VNRX, Insider Trading, Director Purchase, Equity, Warrants, Beneficial Ownership, SEC Form 4, Public Offering